Table 1.
Clinical characteristics of the groups.
| Group 1 (n = 28) | Group 2 (n = 88) | Group 3 (n = 232) | P-value | |
|---|---|---|---|---|
| Age, years | 70.9 ± 7.8 | 69.5 ± 6.4 | 63.7 ± 9.2 | <0.001*† |
| Male, n (%) | 16 (57.1) | 62 (72.1) | 151 (65.1) | 0.479 |
| Paroxysmal AF, n (%) | 6 (21.4%) | 19 (22.1) | 63 (27.2) | 0.186 |
| Hypertension, n (%) | 21 (75.0) | 48 (54.5) | 115 (49.6) | 0.022 |
| CAD, n (%) | 6 (21.4) | 15 (17.0) | 35 (15.1) | 0.220 |
| Diabetes, n (%) | 7 (25.0) | 14 (15.9) | 39 (16.8) | 0.272 |
| Heart failure, n (%) | 5 (17.9) | 12 (13.6) | 27 (11.6) | 0.200 |
| CHA2 DS2-VASc score | 5.1 ± 1.3 | 4.5 ± 1.3 | 1.8 ± 1.4 | <0.001*† |
| LAD, mm | 44.8 ± 4.1 | 42.9 ± 5.2 | 42.0 ± 5.0 | 0.015* |
| LVEDD, mm | 47.0 ± 4.7 | 48.6 ± 4.5 | 47.6 ± 4.1 | 0.096 |
| LVEF, % | 60.7 ± 5.4 | 61.8 ± 5.5 | 62.7 ± 4.4 | 0.051* |
*
p < 0.05, Group 1 vs. Group 3.
†
p < 0.05, Group 2 vs. Group 3.